drugset / Trial / NCT03564444

D2560C00015 FluMist Annual Safety Study 2018

NCT03564444 ↗

Phase 4 Completed 300 enrolled MedImmune LLC
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This prospective annual release study is designed to evaluate the safety of 2 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2018-2019 influenza season.

Timeline

Start
2018-06-06
Primary completion
2018-12-27
Completion
2018-12-27

Outcome

Missed primary endpoint

registry Risk Difference (RD) 0 (95% CI -6.7 to 1.9) NCT03564444 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivalent influenza vaccine Vaccine 1e+07 unknown Intranasal

Indications